Peter G. Schultz, Ph.D.
Chief Executive Officer
Peter G. Schultz graduated from Caltech in 1979 with a B.S. degree in Chemistry (summa cum laude) and continued there for his doctoral degree with Peter Dervan (in 1984). After a postdoctoral year at the Massachusetts Institute of Technology, he moved to the University of California, Berkeley, where he was a Professor of Chemistry, a Principal Investigator at the Lawrence Berkeley National Laboratory and an Investigator in the Howard Hughes Medical Institute. He moved to The Scripps Research Institute in 1999 where he is currently the Chief Executive Officer and Vice Chair. Schultz’s contributions to science include: (1) the discovery of catalytic antibodies, and their use to study fundamental mechanisms of biological and the immune system (2) the development and application of methods to expand the genetic code of living organisms; and (3) the development and application of molecular diversity technologies to problems in chemistry, biology and medicine. Schultz also established the Genomics Institute of the Novartis Research Foundation I 1999 (GNF; La Jolla, CA) and served as its Director until 2010 with some 600 FTE. GNF develops and applies state of the art high throughput chemical, proteomics, genomics and informatics technologies to the identification of novel genes and biological processes, as well as the development of new human therapeutics for cancer, immune, metabolic, cardiovascular and infectious disease. More recently, Schultz established Calibr, which is focused on translational research to create innovative medicines for major unmet medical needs. Schultz is the author of 500+ scientific publications, has trained over 300 coworkers and has received numerous awards including the Alan T. Waterman Award, NSF (1988), the ACS Award in Pure Chemistry (1990), the Wolf Prize in Chemistry (1994), the Paul Erhlich and Ludwig Darmstaedter Award (2002), the ACS Arthur C. Cope Award (2006), and the Solvay Prize (2013). Professor Schultz is a member of the National Academy of Sciences, USA (1993) and the Institute of Medicine of the National Academy of Sciences (1998) and he is active on many editorial and scientific advisory boards. He is a founder of Affymax Research Institute, Symyx Technologies, Syrrx, Kalypsys, Phenomix, Ilypsa, Ambrx, Wildcat Discovery Technologies, and Ardelyx, which have pioneered the application of molecular diversity technologies to challenges in energy, materials and human health.
Matt Tremblay, Ph.D.
Chief Operating Officer
As Chief Operating Officer and Secretary to the Board of Directors, Matt is responsible for the day to day operation of the institute, as well as external relationships with academic, foundation and commercial partners, and works closely with the CEO to develop corporate strategy and advance new business development opportunities. Matt’s group also manages internal research programs and scientific interactions with partner organizations. Matt facilitated the launch of a number of strategic initiatives at Calibr, including drug discovery collaborations with the Juvenile Diabetes Research Foundation, the Bill & Melinda Gates Foundation, Bristol-Myers Squibb, and Pfizer. He has been involved with research at Calibr since its inception in April 2012, leading a team of biologists in the discovery of new therapeutic agents for metabolic, cardiovascular, and autoimmune diseases. Before joining Calibr, Matt led a group at the Genomics Institute of the Novartis Research Foundation (GNF) in drug discovery for type 1 diabetes. Matt earned his Ph.D. in chemistry from Columbia University in 2007 before spending two years as a postdoctoral fellow in Peter Schultz’s lab at The Scripps Research Institute.
James Schaeffer, Ph.D.
Vice President, External Relations
Dr. Jim Schaeffer joined Calibr in June 2014 following a 25 year career at Merck Research Labs (MRL). During his first 15 years at MRL, Jim directed research groups focusing primarily on neuroendocrine-related projects. Jim moved to San Diego in 2004 to assume the role of Merck's "Science Scout" on the West Coast, with the responsibility to identify new opportunities across all therapeutic areas at all stages of development including enabling technologies. During the next ten years, Jim was directly involved in the execution of 15 major agreements with West Coast based organizations. Jim was also directly involved in the formation of a partnership between Merck and Dr. Schultz which lead to the establishment of Calibr. Dr. Schaeffer received his Ph.D. at Baylor College of Medicine and was a post-doctoral fellow in the laboratory of Dr. Julius Axelrod at the National Institute of Mental Health. Prior to joining Merck, Jim was an assistant professor in the Department of Reproductive Medicine in the School of Medicine at UCSD. He is the author of more than 110 articles in peer reviewed journals.
Sabrina Martucci Johnson
Sabrina Martucci Johnson joined Calibr in May 2015. Ms. Johnson brings over 25 years of experience in the life sciences industry. Sabrina’s unique background spans finance, product development, and global marketing. Prior to joining Calibr Sabrina was President of the non-profit specialty pharmaceutical company WomanCare Global Trading, where Sabrina was responsible for new innovation and expanding the global product portfolio in women’s healthcare in over 100 countries. Sabrina was formerly a key member of the executive management team at Cypress Bioscience, Inc. (NASDAQ:CYPB) where she most recently served as Chief Operating Officer and Chief Financial Officer. She previously held marketing and sales positions with Advanced Tissue Sciences and Clonetics Corporation. She began her career in the biotechnology industry as a research scientist with Baxter Healthcare, Hyland Division, working on their recombinant factor VIII program. Sabrina has an MIM from the Thunderbird School of Global Management with honors, a MSc. in Biochemical Engineering from the University of London, University College London, and a BSc. in Biomedical Engineering from Tulane University, where she graduated magna cum laude.